| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Dermatomycoses | D003881 | 17 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Encephalomyelitis, Autoimmune, Experimental | D004681 | 26 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
2E,6E-farnesol
2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
Cross Reference
Introduction
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2E,6E-farnesol?
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
PubChem Associated disorders and diseases
What pathways are associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2E,6E-farnesol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2E,6E-farnesol?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 2E,6E-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schleimer K et al. | Competition between native liver and graft in auxiliary liver transplantation in a rat model. | 2008 | Transplant. Proc. | pmid:18555091 |
| Flint OP et al. | Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. | 1997 | Toxicol. Appl. Pharmacol. | pmid:9221828 |
| Lemaire B et al. | Cytochrome P450 20A1 in zebrafish: Cloning, regulation and potential involvement in hyperactivity disorders. | 2016 | Toxicol. Appl. Pharmacol. | pmid:26853319 |
| Yang SP and Raner GM | Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. | 2005 | Toxicol. Appl. Pharmacol. | pmid:15629189 |
| Winn LM and Wells PG | Evidence for Ras-dependent signal transduction in phenytoin teratogenicity. | 2002 | Toxicol. Appl. Pharmacol. | pmid:12460742 |
| Saito K et al. | An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. | 2017 | Toxicol In Vitro | pmid:27965148 |
| Mussoni L et al. | Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. | 2000 | Thromb. Haemost. | pmid:10928471 |
| Binet L et al. | [Farnesol, psychosedative and spasmolytic drug]. | 1972 Sep-Oct | Therapie | pmid:4405589 |
| Zhang X et al. | Nanomicellar carriers for targeted delivery of anticancer agents. | 2014 | Ther Deliv | pmid:24341817 |
| Fukui S | [Sexual differentiation in heterobasidiomycetous yeasts (author's transl)]. | 1980 | Seikagaku | pmid:7019358 |